Katrina Pyle, NP
Acute Care · Oklahoma City, OKNPI 1295284032
Payments from drug & device makers
Across 630 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Sanofi$867
- Regeneron Healthcare Solutions, Inc.$706
- Mylan Specialty L.p.$693
- plus $4K from 20 others
What the payments were for
- Food & beverage$12,46098%
- Education$2202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 122 | $3,346 |
| GSK | 105 | $1,620 |
| Boehringer Ingelheim | 45 | $1,039 |
| Sanofi | 43 | $867 |
| Regeneron Healthcare Solutions, Inc. | 37 | $706 |
| Mylan Specialty L.p. | 55 | $693 |
| Insmed, Inc. | 23 | $472 |
| United Therapeutics Corporation | 20 | $455 |
| Baxter Healthcare | 23 | $428 |
| Amgen | 23 | $412 |
| Harmony Biosciences LLC | 20 | $394 |
| Jazz Pharmaceuticals Inc. | 12 | $383 |
| Verona Pharma, Inc. | 29 | $362 |
| Actelion Pharmaceuticals US, Inc. | 10 | $315 |
| Viatris Specialty LLC | 17 | $182 |
| Pulmonx Corporation | 3 | $160 |
| Sanofi-aventis U.S. LLC | 3 | $147 |
| Inogen, Inc. | 10 | $135 |
| Philips North America LLC | 8 | $134 |
| Merck | 6 | $131 |
| Axsome Therapeutics, Inc. | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Lilly USA, LLC | 3 | $54 |
| Edwards Lifesciences | 1 | $25 |
| Genentech USA, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,680 in reported general payments places this provider in the 95th percentile of 266 acute care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $177,716 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 121 | $139,897 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $45,569 |
| Spiriva RespimatTiotropium Bromide | 29 | $26,249 |
| Ipratropium Bromide | 344 | $15,811 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $14,786 |
| EliquisApixaban | 11 | $14,749 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $12,662 |
| Roflumilast | 50 | $8,982 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 201 | $8,133 |
| Montelukast Sodium | 331 | $7,177 |
| BreynaBudesonide/Formoterol Fumarate | 24 | $6,029 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $5,978 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $3,797 |
| Fluticasone Propionate | 89 | $2,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,620 | $223,285210 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,346 | $154,683160 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,039 | $38,91156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 acute care providers in Oklahoma.
Other acute care in Oklahoma City
- Karen GregoryOklahoma City$68K
- Deborah PeterOklahoma City$12K
- Christopher GordonOklahoma City$12K
- Kelli LeekOklahoma City$10K
- Scottie SmithOklahoma City$8K
- Maria BacaOklahoma City$7K
- Janet FundaroOklahoma City$7K
- Silvia Olivares MendozaOklahoma City$6K
- Bonnie RenfroOklahoma City$5K
- Vicki OliverOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.